RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aperio Clinical Outcomes, a leading clinical research organization (CRO), announced that Eric Ross has joined the company as Vice President of Business Development to drive new growth and strengthen existing client relationships.
Ross has over 16 years of experience in life sciences, including eight years leading Business Development growth for the CRO industry at MedSource, Chiltern and Ockham Oncology. Prior to this, he served in various Director and Manager Operations roles at Almac and etrials Worldwide where he held senior operations positions in Project Management, Product Management and Global Support Services. Mr. Ross’ experience across various segments of the clinical trial industry allows him to be uniquely attuned to the challenges Aperio’s small and mid-size biotech clients face.
According to Aperio’s Founder and CEO Faye Woolf, “Eric’s appointment comes at a crucial time in the industry. With the rise in complex protocol designs and the growing volume and number of data sources, clinical trials risks have never been greater. These risks are especially palpable for our small and emerging biotech customers. Aperio wants to strengthen our partnerships with the biotech community and educate them on how a data-driven, risk-based approach can help them manage trial risks, increase the overall quality of their clinical development programs, and often save them time and money. Eric’s strong principles, coupled with his operations background and Business Development acumen, will enable Eric to position Aperio to grow strategically in a way that allows Aperio to excel while simultaneously providing the solutions our small- and mid-size biotech customers need.”
“I’m thrilled to be at Aperio, a company that closely aligns with my own values and commitments to quality, transparency and customer-centricity. I believe that relationships and trust are the foundation for biotechs and CROs to work together successfully,” says Ross. “I am excited to leverage my deep industry experience and vast network with the biotech industry to drive strategic growth for Aperio in oncology, CNS and other therapeutic areas.”
View source on: shorturl.at/pBNUZ